Type, timing, and risk factors associated with immune-related adverse event development in patients with advanced genitourinary cancers treated with immune checkpoint inhibitor.
Qin Q, Patel V, Mellgard G, Parikh A, Wang B, Alerasool P, Garcia P, Jaladanki S, Leiter A, Carroll E, Brooks D, Shimol J, Eisenberg E, Gallagher E, Galsky M, Oh W, Tsao C. Type, timing, and risk factors associated with immune-related adverse event development in patients with advanced genitourinary cancers treated with immune checkpoint inhibitor. Journal Of Clinical Oncology 2020, 38: 480-480. DOI: 10.1200/jco.2020.38.6_suppl.480.Peer-Reviewed Original ResearchImmune related adverse eventsImmune checkpoint inhibitorsRenal cell carcinomaCheckpoint inhibitorsSystemic steroidsUrothelial carcinomaAssociated with immune related adverse eventsCancer treated with immune checkpoint inhibitorsDevelopment of immune related adverse eventsImmune-related adverse events developmentImmune checkpoint inhibitor doseAdvanced urothelial carcinomaPatient baseline characteristicsClinical risk factorsRelated adverse eventsFisher's exact testAdverse events developmentAdvanced UCICI-treatedIrAE developmentCell carcinomaMedian timeTreatment courseBaseline characteristicsClinical outcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply